YYC 506
Alternative Names: YYC-506; YYC506-T/YYC506-ALatest Information Update: 02 Oct 2021
At a glance
- Originator Yooyoung Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dyslipidaemias
Most Recent Events
- 29 Jan 2021 Phase-III clinical trials in Dyslipidaemias in South Korea (PO) (NCT04858308)
- 07 Jan 2021 Yooyoung Pharmaceutical initiates enrolment in a phase I trial for Dyslipidaemias (In Volunteers) in South Korea (NCT04874129)
- 23 Mar 2020 Yooyoung Pharmaceutical completes a phase I trial in Dyslipidaemias (In volunteers) in South Korea (NCT04874142)